Summary
LTF-CG is a synthetic long-acting analog of the pancreatic peptide amylin. It is studied in literature on amylin-receptor pharmacology, energy-metabolism modeling, and as a frequent comparator in combination studies alongside GLP-1 receptor agonists.
Overview
LTF-CG is a lipidated amylin analog engineered for extended functional half-life relative to native amylin. It is one of the newer reference compounds in amylin-pharmacology literature and is studied in receptor-binding, signaling, and energy-metabolism work alongside the broader incretin-pharmacology research program.
Research Background
LTF-CG was developed at Novo Nordisk and described in the amylin-pharmacology literature in the late 2010s and early 2020s. The amylin-receptor family consists of calcitonin-receptor heterodimers with different RAMP (receptor activity-modifying protein) partners, and LTF-CG engages these receptors as a long-acting analog of the native hormone.
Mechanisms Studied
Mechanistic interest centers on its agonist activity at amylin receptors (calcitonin-receptor heterodimers with RAMP1/2/3 partners), the structural basis for its extended half-life, and the relationship between amylin signaling and other metabolic-axis pathways. Combination studies with GLP-1 receptor agonists are a particularly active area.
Published Research Summary
Enebo et al. (2021) report on the preclinical and early human-research pharmacology of LTF-CG. Combination studies with LTF-SM (the CagriSema preparation) are reported in subsequent literature. Reviews of amylin-pharmacology (Roth 2013, Hay 2017) frame the broader receptor biology.
Quality & Verification
For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.
References & Published Research
- Enebo LB et al. — Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of LTF-CG with LTF-SM
- Hay DL et al. — Amylin: Pharmacology, Physiology, and Clinical Potential (review)
- Roth JD — Amylin and the regulation of appetite and adiposity (review)